Tonapofylline: A selective adenosine-1 receptor antagonist for the treatment of heart failure

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 14, 2010, Pages 2405-2415

  Ensor, Christopher R ^a   Russell, Stuart D ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Adenosine; Cardiorenal syndrome; Heart failure; Tonapofylline

Indexed keywords

3 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)BICYCLO[2.2.2]OCTAN 1 YL]PROPIONIC ACID; NAXIFYLLINE; ROLOFYLLINE; TONAPOFYLLINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; HEART FAILURE; HEART INFARCTION SIZE; HUMAN; MEDLINE; NONHUMAN; REVIEW; SEIZURE; SINGLE DRUG DOSE; SODIUM URINE LEVEL; STRUCTURE ACTIVITY RELATION;

ADENOSINE A1 RECEPTOR ANTAGONISTS; CARDIOVASCULAR AGENTS; HEART FAILURE; HUMANS; XANTHINES;

EID: 77956574334     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.514605     Document Type: Review

References (44)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article: a report of the American College of Cardiology/ American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:1825-1852
2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association statistics committee and stroke statistics committee. Circulation 2008;117:e25-146
3. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717
4. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321
5. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial: (COMET): randomized controlled trial. Lancet 2003;362:7-13
6. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/AL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007
7. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-1539
8. Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 2007;3:637
9. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008;34:957-962
10. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-689
11. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-678
12. Fonarow GC, Adams KF, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:32-40G
13. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology foundation/American Heart Association task force on practice guidelines. Circulation 2009;119:1977-2016
14. Adams KF, Lindenfeld J, Arnold JMO, et al. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006;12:e1-122
15. Lauschke A, Teichgraber UK, Frei U, et al. Low-dose dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 2006;69:1669-1674
16. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-683
17. Szabo T, Felger D, von Haehling S, et al. Overview of emerging pharmacotherapy in chronic heart failure. Expert Opin Pharmacother 2009;10:2055-2074
18. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-1971
19. Goldsmith SR, Elkayam U, Haught WH, et al. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008;14:641-647
20. Slawsky MT, Givertz MM. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother 2009;10:311-322
21. Gottlieb SS. Adenosine A1 antagonists and the cardiorenal syndrome. Curr Heart Fail Rep 2008;5:105-109
22. Shah RH, Frishman WH. Adenosine1 receptor antagonism. A new therapeutic approach for the treatment of decompensated heart failure. Cardiol Rev 2009;17:125-131
23. Kuan CJ, Herzer WA, Jackson EK. An experimental paradigm for investigating the role of endogenous adenosine/ A1 receptor interactions in vivo. J Pharmacol Exp Ther 1992;263:657-662
24. Vu C, Kiesman WF, Conlon PR, et al. Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists. J Med Chem 2006;49:7132-7139
25. Kiesman WF, Zhao J, Conlon PR, et al. Potent and orally bioavailable 8-bicyclo [2.2.2]octylxanthines as adenosine a1 receptor antagonists. J Med Chem 2006;49:7119-7131
26. Vitzhum H, Weiss B, Bachleitner W, et al. Gene expression of adenosine receptors along the nephron. Kidney Int 2004;65:1180-1190
27. Doggrell SA. BG-9928. Curr Opin Invest Drug 2005;6:962-968
28. Ticho B, Whalley E, Gill A, et al. Renal effects of BG9928, an A1 adenosine receptor antagonist, in rats and nonhuman primates. Drug Dev Res 2003;58:486-492
29. Acuhampach JA, Jin X, Moore J, et al. Comparison of three different A1 adenosine receptor antagonists on the infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J Pharmacol Exp Ther 2004;308:846-856
30. Kuan CJ, Herzer WA, Jackson EK. Cardiovascular and renal effects of blocking A1 adenosine receptors. J Cardiovasc Pharmacol 1993;21:822-828
31. Gellai M, Schreiner FG, Ruffolo RR, et al. CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity. J Pharmacol Exp Ther 1998;286:1191-1196
32. Wilcox CS, Welch WJ, Schreiner GF, et al. Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol 1999;10:714-720
33. Yang JN, Chen JF, Fredholm BB. Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. Am J Physiol Heart Circ Physiol 2009;296:H1141-9
34. Lucas DG, Hendrick JW, Sample JA, et al. Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure. J Am Coll Surg 2002;194:603-609
35. Mitrovic V, Seferovic P, Dodic S, et al. Cardio-renal effects of the A1 adenosine receptor antagonist SLV-320 in patients with heart failure. Circ Heart Fail 2009;2:523-531
36. Pfister JR, Belardinelli L, Lee G, et al. Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]- xanthine. J Med Chem 1997;40:1773-1778
37. Rotella D. Adenosine receptor symposium. American chemical society. Boston: IDDB meeting report; 2002
38. Li ZM, Tao Y, Korter K, TenHoor CCS. Cross-species metabolism profiling of BG9928, a potent antagonist of adenosine A1 receptor [abstract 272]. Drug Metab Rev 2004;36:S1
39. Ticho B, Marbury T, Zhu Y, et al. Renal effects of BG9928, an A1 adenosine antagonist, in rats and healthy human subjects. Drug Dev Res 2003;56:556
40. Greenberg B, Thomas I, Banish D, et al. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure. J Am Coll Cardiol 2007;50:600-606
41. Nieminen M, Chertow G, Deykin A, et al. Phase 2b study to assess the safety and tolerability of IV tonapofylline in subjects with acute decompensated heart failure (ADHF) and renal insufficiency (TRIDENT-1). Presented at the European Society of Cardiology Heart Failure Congress; 30 May 2010; Berlin, Germany
42. Gottlieb SS, Ticho B, Deykin A, et al. The effects of BG9928, an adenosine A1 receptor antagonist, in patients with congestive heart failure. J Clin Pharmacol 2010; In press
43. Gottleib SS, Skettino SL, Wolff A, et al. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 2000;35:56-59
44. Giverz MM, Massie BM, Fields TK, et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007;50:1551-1560